Skip to main content
Erschienen in:

14.03.2017 | Neuropathischer Schmerz | CME

Chemotherapie-induzierte periphere Neuropathie und neuropathischer Schmerz

verfasst von: PD Dr. U. Schuler, S. Heller

Erschienen in: Der Schmerz | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Chemotherapie ist in der medialen Wahrnehmung vor allem mit Übelkeit, Erbrechen und Haarausfall assoziiert. Längerfristig ist für die Patienten oft bedeutsamer, dass sich eine periphere Neuropathie, genauer eine chemotherapieinduzierte periphere Neuropathie (CIPN), entwickelt. Die CIPN stellt bei einer Reihe von antineoplastischen Substanzen eine funktionell stark beeinträchtigende Nebenwirkung dar, deren Prävention und Therapie eine wichtige Aufgabe ist. Neben vielen als ineffektiv belegten Interventionen zeichnet sich ab, dass physiotherapeutische Maßnahmen und eventuell die prophylaktische Anwendung von Kälte vorbeugend hilfreich sind. Randomisierte Studien zur Therapie der schmerzhaften CIPN haben positive Daten für Duloxetin und in geringerem Umfang für Venlafaxin geliefert.
Literatur
1.
2.
Zurück zum Zitat Johnson IS, Armstrong JG, Gorman M et al (1963) The vinca alkaloids: a new class of oncolytic agents. Cancer Res 23:1390–1427PubMed Johnson IS, Armstrong JG, Gorman M et al (1963) The vinca alkaloids: a new class of oncolytic agents. Cancer Res 23:1390–1427PubMed
3.
Zurück zum Zitat Carbone PP, Bono V, Frei E et al (1963) Clinical studies with vincristine. Blood 21:640–647PubMed Carbone PP, Bono V, Frei E et al (1963) Clinical studies with vincristine. Blood 21:640–647PubMed
4.
Zurück zum Zitat Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303CrossRefPubMed Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303CrossRefPubMed
5.
Zurück zum Zitat Hadley D, Herr HW (1979) Peripheral neuropathy associated with cis–dichlorodiammineplatinum (II) treatment. Cancer 44:2026–2028CrossRefPubMed Hadley D, Herr HW (1979) Peripheral neuropathy associated with cis–dichlorodiammineplatinum (II) treatment. Cancer 44:2026–2028CrossRefPubMed
6.
Zurück zum Zitat Wiernik PH, Schwartz EL, Strauman JJ et al (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486–2493PubMed Wiernik PH, Schwartz EL, Strauman JJ et al (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486–2493PubMed
9.
Zurück zum Zitat Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clinoncol 32:1941–1967CrossRef Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clinoncol 32:1941–1967CrossRef
10.
Zurück zum Zitat Loprinzi CL, Reeves BN, Dakhil SR et al (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clinoncol 29:1472–1478CrossRef Loprinzi CL, Reeves BN, Dakhil SR et al (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clinoncol 29:1472–1478CrossRef
11.
Zurück zum Zitat Pachman DR, Qin R, Seisler DK et al (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clinoncol 33:3416–3422CrossRef Pachman DR, Qin R, Seisler DK et al (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clinoncol 33:3416–3422CrossRef
12.
Zurück zum Zitat Postma TJ, Aaronson NK, Heimans JJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135–1139CrossRefPubMed Postma TJ, Aaronson NK, Heimans JJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135–1139CrossRefPubMed
14.
Zurück zum Zitat Mucke M, Cuhls H, Radbruch L et al (2014) Quantitative sensory testing. Schmerz 28:635–646CrossRefPubMed Mucke M, Cuhls H, Radbruch L et al (2014) Quantitative sensory testing. Schmerz 28:635–646CrossRefPubMed
15.
Zurück zum Zitat Gossrau G, Reichmann H, Sabatowski R (2008) Elektrophysiologische Messverfahren in der Schmerztherapie. Schmerz 22:471–479CrossRefPubMed Gossrau G, Reichmann H, Sabatowski R (2008) Elektrophysiologische Messverfahren in der Schmerztherapie. Schmerz 22:471–479CrossRefPubMed
17.
Zurück zum Zitat Finnerup NB, Haroutounian S, Kamerman P et al (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain 157:1599–1606CrossRefPubMedPubMedCentral Finnerup NB, Haroutounian S, Kamerman P et al (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain 157:1599–1606CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Kautio AL, Haanpaa M, Kautiainen H et al (2011) Burden of chemotherapy-induced neuropathy – a cross-sectional study. Support Care Cancer 19:1991–1996CrossRefPubMed Kautio AL, Haanpaa M, Kautiainen H et al (2011) Burden of chemotherapy-induced neuropathy – a cross-sectional study. Support Care Cancer 19:1991–1996CrossRefPubMed
19.
Zurück zum Zitat Gewandter JS, Fan L, Magnuson A et al (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21:2059–2066CrossRefPubMedPubMedCentral Gewandter JS, Fan L, Magnuson A et al (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21:2059–2066CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Tofthagen C, Visovsky C, Berry DL (2012) Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research. Oncol Nurs Forum 39:E416–E424CrossRefPubMedPubMedCentral Tofthagen C, Visovsky C, Berry DL (2012) Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research. Oncol Nurs Forum 39:E416–E424CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Padman S, Lee J, Kumar R et al (2015) Late effects of oxaliplatin-induced peripheral neuropathy (LEON)-cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. Support Care Cancer 23:861–869CrossRefPubMed Padman S, Lee J, Kumar R et al (2015) Late effects of oxaliplatin-induced peripheral neuropathy (LEON)-cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. Support Care Cancer 23:861–869CrossRefPubMed
22.
Zurück zum Zitat Ramchandren S, Leonard M, Mody RJ et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 14:184–189CrossRefPubMed Ramchandren S, Leonard M, Mody RJ et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 14:184–189CrossRefPubMed
23.
Zurück zum Zitat Briani C, Argyriou AA, Izquierdo C et al (2014) Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2‑year follow-up study. J Peripher Nerv Syst 19:299–306CrossRefPubMed Briani C, Argyriou AA, Izquierdo C et al (2014) Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2‑year follow-up study. J Peripher Nerv Syst 19:299–306CrossRefPubMed
24.
Zurück zum Zitat Rajabally YA (2011) Neuropathy and paraproteins: review of a complex association. Eur J Neurol 18:1291–1298CrossRefPubMed Rajabally YA (2011) Neuropathy and paraproteins: review of a complex association. Eur J Neurol 18:1291–1298CrossRefPubMed
25.
Zurück zum Zitat The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72CrossRef The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72CrossRef
27.
Zurück zum Zitat Merz M, Salwender H, Haenel M et al (2016) Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica 101:e485–e487CrossRefPubMedPubMedCentral Merz M, Salwender H, Haenel M et al (2016) Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica 101:e485–e487CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431–440CrossRefPubMed Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431–440CrossRefPubMed
29.
Zurück zum Zitat Moriyama B, Henning SA, Leung J et al (2012) Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 55:290–297CrossRefPubMed Moriyama B, Henning SA, Leung J et al (2012) Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 55:290–297CrossRefPubMed
30.
Zurück zum Zitat Harnicar S, Adel N, Jurcic J (2009) Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract 15:175–182CrossRefPubMed Harnicar S, Adel N, Jurcic J (2009) Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract 15:175–182CrossRefPubMed
31.
Zurück zum Zitat Hashimoto N, Yokoyama K, Sadahira K et al (2012) Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy. Int J Hematol 96:758–763CrossRefPubMed Hashimoto N, Yokoyama K, Sadahira K et al (2012) Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy. Int J Hematol 96:758–763CrossRefPubMed
32.
Zurück zum Zitat Hogan-Dann CM, Fellmeth WG, McGuire SA et al (1984) Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 252:2862–2863CrossRefPubMed Hogan-Dann CM, Fellmeth WG, McGuire SA et al (1984) Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 252:2862–2863CrossRefPubMed
33.
Zurück zum Zitat Lamba JK, Fridley BL, Ghosh TM et al (2014) Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 15:1565–1574CrossRefPubMedPubMedCentral Lamba JK, Fridley BL, Ghosh TM et al (2014) Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 15:1565–1574CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Hertz DL, Motsinger-Reif AA, Drobish A et al (2012) CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 134:401–410CrossRefPubMedPubMedCentral Hertz DL, Motsinger-Reif AA, Drobish A et al (2012) CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 134:401–410CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Favis R, van Sun Y et al (2011) Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 21:121–129CrossRefPubMed Favis R, van Sun Y et al (2011) Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 21:121–129CrossRefPubMed
37.
Zurück zum Zitat Broyl A, Corthals SL, Jongen JL et al (2010) Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11:1057–1065CrossRefPubMed Broyl A, Corthals SL, Jongen JL et al (2010) Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11:1057–1065CrossRefPubMed
38.
39.
Zurück zum Zitat Hershman DL, Till C, Wright JD et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol 34:3014–3022CrossRefPubMed Hershman DL, Till C, Wright JD et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol 34:3014–3022CrossRefPubMed
40.
Zurück zum Zitat Loprinzi CL, Qin R, Dakhil SR et al (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997–1005CrossRefPubMed Loprinzi CL, Qin R, Dakhil SR et al (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997–1005CrossRefPubMed
43.
Zurück zum Zitat Glimelius B, Manojlovic N, Pfeiffer P et al (2016) Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 34(suppl): (abstr 10018). http://meetinglibrary.asco.org/content/166655-176 Glimelius B, Manojlovic N, Pfeiffer P et al (2016) Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 34(suppl): (abstr 10018). http://​meetinglibrary.​asco.​org/​content/​166655-176
44.
Zurück zum Zitat Kautio AL, Haanpaa M, Saarto T et al (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 35:31–39CrossRefPubMed Kautio AL, Haanpaa M, Saarto T et al (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 35:31–39CrossRefPubMed
45.
Zurück zum Zitat Hammack JE, Michalak JC, Loprinzi CL et al (2002) Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98:195–203CrossRefPubMed Hammack JE, Michalak JC, Loprinzi CL et al (2002) Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98:195–203CrossRefPubMed
46.
Zurück zum Zitat Rao RD, Michalak JC, Sloan JA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118CrossRefPubMed Rao RD, Michalak JC, Sloan JA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118CrossRefPubMed
47.
Zurück zum Zitat Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367CrossRefPubMedPubMedCentral Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Hirayama Y, Ishitani K, Sato Y et al (2015) Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 20:866–871CrossRefPubMed Hirayama Y, Ishitani K, Sato Y et al (2015) Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 20:866–871CrossRefPubMed
49.
Zurück zum Zitat Konno S, Oda N, Ochiai T et al (2016) Randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in japanese patients with chronic low back pain. Spine 41:1709–1717CrossRefPubMedPubMedCentral Konno S, Oda N, Ochiai T et al (2016) Randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in japanese patients with chronic low back pain. Spine 41:1709–1717CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Durand JP, Deplanque G, Montheil V et al (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200–205CrossRefPubMed Durand JP, Deplanque G, Montheil V et al (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200–205CrossRefPubMed
51.
Zurück zum Zitat Sun Y, Shu Y, Liu B et al (2016) A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy. Exp Ther Med. 12(6):4017–4024 Sun Y, Shu Y, Liu B et al (2016) A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy. Exp Ther Med. 12(6):4017–4024
52.
Zurück zum Zitat Hershman DL, Unger JM, Crew KD et al (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31:2627–2633CrossRefPubMedPubMedCentral Hershman DL, Unger JM, Crew KD et al (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31:2627–2633CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Nishioka M, Shimada M, Kurita N et al (2011) The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 16:322–327CrossRefPubMed Nishioka M, Shimada M, Kurita N et al (2011) The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 16:322–327CrossRefPubMed
54.
Zurück zum Zitat Oki E, Emi Y, Kojima H et al (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20:767–775CrossRefPubMed Oki E, Emi Y, Kojima H et al (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20:767–775CrossRefPubMed
55.
Zurück zum Zitat Kottschade LA, Sloan JA, Mazurczak MA et al (2011) The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 19:1769–1777CrossRefPubMed Kottschade LA, Sloan JA, Mazurczak MA et al (2011) The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 19:1769–1777CrossRefPubMed
56.
Zurück zum Zitat Fainsinger RL, Fairchild A, Nekolaichuk C et al (2009) Is pain intensity a predictor of the complexity of cancer pain management? J Clin Oncol 27:585–590CrossRefPubMed Fainsinger RL, Fairchild A, Nekolaichuk C et al (2009) Is pain intensity a predictor of the complexity of cancer pain management? J Clin Oncol 27:585–590CrossRefPubMed
57.
Zurück zum Zitat Nagashima M, Ooshiro M, Moriyama A et al (2014) Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support Care Cancer 22:1579–1584CrossRefPubMedPubMedCentral Nagashima M, Ooshiro M, Moriyama A et al (2014) Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support Care Cancer 22:1579–1584CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Cartoni C, Brunetti GA, Federico V et al (2012) Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Support Care Cancer 20:2621–2626CrossRefPubMed Cartoni C, Brunetti GA, Federico V et al (2012) Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Support Care Cancer 20:2621–2626CrossRefPubMed
59.
Zurück zum Zitat Kanbara T, Nakamura A, Shibasaki M et al (2014) Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G‑protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model. Neurosci Lett 580:119–124CrossRefPubMed Kanbara T, Nakamura A, Shibasaki M et al (2014) Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G‑protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model. Neurosci Lett 580:119–124CrossRefPubMed
60.
Zurück zum Zitat Thibault K, Calvino B, Rivals I et al (2014) Molecular mechanisms underlying the enhanced analgesic effect of oxycodone compared to morphine in chemotherapy-induced neuropathic pain. PLoSOne 9:e91297CrossRefPubMedPubMedCentral Thibault K, Calvino B, Rivals I et al (2014) Molecular mechanisms underlying the enhanced analgesic effect of oxycodone compared to morphine in chemotherapy-induced neuropathic pain. PLoSOne 9:e91297CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Sommer C, Welsch P, Klose P et al (2015) Opioide bei chronischem neuropathischem Schmerz. Systematische Ubersicht und Metaanalyse der Wirksamkeit, Vertraglichkeit und Sicherheit in randomisierten, placebokontrollierten Studien uber mindestens 4 Wochen. Schmerz 29:35–46CrossRefPubMed Sommer C, Welsch P, Klose P et al (2015) Opioide bei chronischem neuropathischem Schmerz. Systematische Ubersicht und Metaanalyse der Wirksamkeit, Vertraglichkeit und Sicherheit in randomisierten, placebokontrollierten Studien uber mindestens 4 Wochen. Schmerz 29:35–46CrossRefPubMed
63.
Zurück zum Zitat Sugiyama Y, Sakamoto N, Ohsawa M et al (2016) A retrospective study on the effectiveness of switching to oral methadone for relieving severe cancer-related neuropathic pain and limiting adjuvant analgesic use in Japan. J Palliat Med 19:1051–1059CrossRefPubMed Sugiyama Y, Sakamoto N, Ohsawa M et al (2016) A retrospective study on the effectiveness of switching to oral methadone for relieving severe cancer-related neuropathic pain and limiting adjuvant analgesic use in Japan. J Palliat Med 19:1051–1059CrossRefPubMed
64.
Zurück zum Zitat Langford RM, Knaggs R, Farquhar-Smith P et al (2016) Is tapentadol different from classical opioids? A review of the evidence. Br J Pain 10:217–221CrossRefPubMedPubMedCentral Langford RM, Knaggs R, Farquhar-Smith P et al (2016) Is tapentadol different from classical opioids? A review of the evidence. Br J Pain 10:217–221CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Ramsenthaler C, Kane P, Gao W et al (2016) Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol 97:416–429CrossRefPubMed Ramsenthaler C, Kane P, Gao W et al (2016) Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol 97:416–429CrossRefPubMed
66.
Zurück zum Zitat Attal N, Cruccu G, Baron R et al (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17(88):1113–e88CrossRefPubMed Attal N, Cruccu G, Baron R et al (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17(88):1113–e88CrossRefPubMed
67.
Zurück zum Zitat Schwenk M, Grewal GS, Holloway D et al (2016) Interactive Sensor-Based Balance Training in Older Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Trial. Gerontology 62:553–563CrossRefPubMed Schwenk M, Grewal GS, Holloway D et al (2016) Interactive Sensor-Based Balance Training in Older Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Trial. Gerontology 62:553–563CrossRefPubMed
Metadaten
Titel
Chemotherapie-induzierte periphere Neuropathie und neuropathischer Schmerz
verfasst von
PD Dr. U. Schuler
S. Heller
Publikationsdatum
14.03.2017
Verlag
Springer Medizin
Erschienen in
Der Schmerz / Ausgabe 4/2017
Print ISSN: 0932-433X
Elektronische ISSN: 1432-2129
DOI
https://doi.org/10.1007/s00482-017-0198-x

Weitere Artikel der Ausgabe 4/2017

Der Schmerz 4/2017 Zur Ausgabe